載入中
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
收盤時
US$2.65
−US$0.01 · -0.38%
盤後
US$2.70
+US$0.05 · +1.89%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
日內區間
目前US$2.65
52週區間
目前US$2.65
盤中時間採用ET。市場資料可能有所延遲。
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
日內區間
目前US$2.65
52週區間
目前US$2.65
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4.2萬 USD | 18.1萬 USD | — | 13.4萬 USD | 57.1萬 USD |
| 銷貨成本 | 4.2萬 USD | 17.2萬 USD | 5.6萬 USD | 16.5萬 USD | 37.3萬 USD |
| 毛利 | — | 9000 USD | −5.6萬 USD | −3.1萬 USD | 19.8萬 USD |
| 研究與開發 | 600.4萬 USD | 449.9萬 USD | 445.4萬 USD | 578.4萬 USD | 677.1萬 USD |
| 銷售、一般及管理費用 | 552.5萬 USD | 509.5萬 USD | 443萬 USD | 725.3萬 USD | 569萬 USD |
| 營業費用 | 1152.9萬 USD | 959.4萬 USD | 888.4萬 USD | 1303.7萬 USD | 1241.5萬 USD |
| 利息收入 | — | 5.8萬 USD | 3.1萬 USD | 8.3萬 USD | — |
| 利息支出 | — | — | — | — | 2.9萬 USD |
| 折舊和攤銷 | 3萬 USD | 4.6萬 USD | 5.6萬 USD | 6.4萬 USD | 5.3萬 USD |
| 營業利益 | −1152.9萬 USD | −958.5萬 USD | −894萬 USD | −1306.8萬 USD | −1221.7萬 USD |
| 淨利 | −1143.9萬 USD | −954.1萬 USD | −888.9萬 USD | −1307.1萬 USD | −1218.7萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$9.00
上漲空間 239.62%評級樣本有限，僅4項
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
